Insmed (NASDAQ:INSM) Coverage Initiated at Barclays

Equities researchers at Barclays began coverage on shares of Insmed (NASDAQ:INSM) in a note issued to investors on Tuesday, Marketbeat.com reports. The brokerage set an “overweight” rating and a $231.00 price target on the biopharmaceutical company’s stock. Barclays‘s price target would indicate a potential upside of 46.69% from the company’s previous close.

Other analysts also recently issued research reports about the company. Rothschild & Co Redburn assumed coverage on Insmed in a report on Thursday, December 4th. They issued a “buy” rating and a $263.00 price target on the stock. Royal Bank Of Canada increased their target price on Insmed from $197.00 to $200.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 21st. Evercore ISI reiterated an “outperform” rating and issued a $180.00 target price on shares of Insmed in a research note on Wednesday, October 1st. Rothschild Redb raised shares of Insmed to a “strong-buy” rating in a report on Thursday, December 4th. Finally, Cantor Fitzgerald increased their price objective on shares of Insmed from $216.00 to $230.00 and gave the stock an “overweight” rating in a report on Tuesday, December 16th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and an average price target of $205.83.

Insmed Stock Performance

INSM traded up $1.59 during trading hours on Tuesday, hitting $157.48. 451,789 shares of the stock were exchanged, compared to its average volume of 2,606,148. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.63 and a quick ratio of 4.34. Insmed has a 12 month low of $60.40 and a 12 month high of $212.75. The stock has a 50-day simple moving average of $181.91 and a 200-day simple moving average of $157.83. The stock has a market cap of $33.59 billion, a price-to-earnings ratio of -25.47 and a beta of 1.08.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). Insmed had a negative return on equity of 183.55% and a negative net margin of 264.83%.The business had revenue of $142.34 million during the quarter, compared to the consensus estimate of $114.33 million. During the same quarter in the previous year, the business posted ($1.27) earnings per share. The company’s quarterly revenue was up 52.4% compared to the same quarter last year. Analysts anticipate that Insmed will post -4.56 earnings per share for the current year.

Insider Activity at Insmed

In other Insmed news, insider Michael Alexander Smith sold 1,053 shares of the company’s stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $174.17, for a total value of $183,401.01. Following the completion of the sale, the insider directly owned 57,037 shares in the company, valued at $9,934,134.29. This represents a 1.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Sara Bonstein sold 1,447 shares of the stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $174.17, for a total value of $252,023.99. Following the transaction, the chief financial officer directly owned 80,506 shares of the company’s stock, valued at approximately $14,021,730.02. The trade was a 1.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 296,799 shares of company stock valued at $54,296,286. 3.00% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. CIBC Private Wealth Group LLC lifted its holdings in Insmed by 42.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 53 shares during the last quarter. Kingsview Wealth Management LLC raised its holdings in shares of Insmed by 2.7% in the 3rd quarter. Kingsview Wealth Management LLC now owns 2,321 shares of the biopharmaceutical company’s stock worth $334,000 after purchasing an additional 60 shares in the last quarter. Choreo LLC lifted its stake in Insmed by 2.9% during the third quarter. Choreo LLC now owns 2,319 shares of the biopharmaceutical company’s stock valued at $334,000 after purchasing an additional 65 shares during the last quarter. ORG Partners LLC lifted its stake in Insmed by 12.7% during the fourth quarter. ORG Partners LLC now owns 657 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 74 shares during the last quarter. Finally, Spire Wealth Management boosted its holdings in Insmed by 11.5% during the third quarter. Spire Wealth Management now owns 777 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 80 shares in the last quarter.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.